×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!
   

Global Forum: Driving Ideas to Action

August 23, 2017

This recent article published in DIA's Global Forum looks at the benefits and challenges of FDA's Accelerated Pathways. According to the FDA’s annual report, two-thirds of novel drugs approved in 2015 used at least one Accelerated Pathway, while a third used two or more.

In order to better understand how major US payers view Accelerated Pathways products, PAREXEL and the non-profit, non-partisan Network for Excellence in Healthcare Innovation (NEHI), conducted a survey of 20 national, regional, public, and private payers whose coverage decisions impact a total of 228 million patients. See the results and commentary in this short article.

Previous Flipbook
Playing Defense In A Riskier Commercial Environment For Cancer Drugs
Playing Defense In A Riskier Commercial Environment For Cancer Drugs

Click here to read about defensive strategies you can take to mitigate commercial risks.

Next Flipbook
Virtual Event Solutions
Virtual Event Solutions

Find out more about virtual meeting technology here!